Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study

Heii Arai, Yu Nakamura, Masamoto Taguchi, Hiroyuki Kobayashi, Keita Yamauchi, Lon S. Schneider

研究成果: Article査読

13 被引用数 (Scopus)

抄録

Introduction We studied the mortality risk of long term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan to determine improved treatment protocols. Methods This 24-week prospective cohort study included 10,079 Japanese AD patients (female, 69%; average age, 81 years) under routine clinical care in 357 medical sites. The antipsychotic medication history was varied (63.7% were long-term users). Mortality rates and odds ratio were analyzed (initial 10 weeks and from 11–24 weeks). Results The antipsychotic exposed group with shorter treatment periods had a higher mortality risk compared to controls. The newly prescribed users (antipsychotic treatment started during the follow-up) showed increased mortality (9.4% during the 11–24 week period). Conclusions New use of antipsychotic drugs represents a distinct risk for mortality; those on long-term antipsychotic therapy seem to be at less risk. The warning issued 10 years earlier on antipsychotics use for AD patients should be reviewed.

本文言語English
ページ(範囲)823-830
ページ数8
ジャーナルAlzheimer's and Dementia
12
7
DOI
出版ステータスPublished - 2016 7月 1

ASJC Scopus subject areas

  • 疫学
  • 健康政策
  • 発達神経科学
  • 臨床神経学
  • 老年医学
  • 精神医学および精神衛生
  • 細胞および分子神経科学

フィンガープリント

「Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル